Use of statins in CNS disorders

被引:103
作者
Cucchiara, B [1 ]
Kasner, SE [1 ]
机构
[1] Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA
关键词
HMG-CoA reductase inhibitors; stroke; statins; nitric oxide; cytokines; neuroprotection;
D O I
10.1016/S0022-510X(01)00529-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
It is well established that 3-hydroxy-3 -methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors ("statins") reduce cholesterol levels and prevent coronary heart disease (CHD). Although a causal relation between elevated cholesterol levels and stroke has not been well defined, a number of large secondary prevention studies and meta-analyses have shown that statin therapy reduces stroke in patients with CHD and hypercholesterolemia. In addition to the vascular effects of statins (stabilization of atherosclerotic plaques, decreased carotid intimal-medial thickness), there are increasing data to suggest that these agents have additional properties that are potentially neuroprotective. These include endothelial protection via actions on the nitric oxide synthase system, as well as antioxidant, anti-inflammatory and anti-platelet effects. These actions of statins might have potential uses in other neurological disorders such as Alzheimer's disease and certain types of brain tumors. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:81 / 89
页数:9
相关论文
共 112 条
[1]  
Alessandri C, 1996, HAEMOSTASIS, V26, P214
[2]   Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin [J].
Alfon, J ;
Royo, T ;
Garcia-Moll, X ;
Badimon, L .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (07) :1812-1817
[3]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[4]   Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS .
ATHEROSCLEROSIS, 1998, 138 (02) :271-280
[5]   Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy [J].
Aviram, M ;
Hussein, O ;
Rosenblat, M ;
Schlezinger, S ;
Hayek, T ;
Keidar, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 (01) :39-45
[6]   Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells [J].
Baetta, R ;
Donetti, E ;
Comparato, C ;
Calore, M ;
Rossi, A ;
Teruzzi, C ;
Paoletti, R ;
Fumagalli, R ;
Soma, MR .
PHARMACOLOGICAL RESEARCH, 1997, 36 (02) :115-121
[7]  
Baldassarre D, 1999, NUTR METAB CARDIOVAS, V9, P108
[8]   Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery [J].
Bandoh, T ;
Mitani, H ;
Niihashi, M ;
Kusumi, Y ;
Ishikawa, J ;
Kimura, M ;
Totsuka, T ;
Sakurai, I ;
Hayashi, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 315 (01) :37-42
[9]   HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages [J].
Bellosta, S ;
Via, D ;
Canavesi, M ;
Pfister, P ;
Fumagalli, R ;
Paoletti, R ;
Bernini, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (11) :1671-1678
[10]   ELEVATED SERUM-CHOLESTEROL IS A RISK FACTOR FOR BOTH CORONARY HEART-DISEASE AND THROMBOEMBOLIC STROKE IN HAWAIIAN JAPANESE MEN - IMPLICATIONS OF SHARED RISK [J].
BENFANTE, R ;
YANO, K ;
HWANG, LJ ;
CURB, JD ;
KAGAN, A ;
ROSS, W .
STROKE, 1994, 25 (04) :814-820